Nycomed Expects More Dealmaking in Russia; Prepares Daxas Rollout In Turkey

Swiss drug maker Nycomed Pharma AS aims to increase revenues from emerging markets by 150% by 2015. The Zurich-based private equity-owned company has seen double-digit growth in Russia and Latin American markets in the past year, and now it is preparing for more deal-making from Moscow and a major product launch in Turkey to accelerate the growth